- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06459648
Studie for å forhindre kronifisering av migrene gjennom prediksjon av respons på behandling med anti-CGRP-antistoffer (PREDI-CGRP)
Prediksjonsstudie eller respons på behandling med anti-CGRP monoklonale antistoffer ved migrene
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.
At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Aragon
-
Zaragoza, Aragon, Spania, 50009
- Hospital Clínico Universitario Lozano Blesa
-
-
Basque Country
-
Donostia / San Sebastian, Basque Country, Spania, 20014
- Hospital Universitario Donostia
-
-
Cantabria
-
Santander, Cantabria, Spania, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Valladolid, Castille and León, Spania, 47010
- Hospital Clínico Universitario de Valladolid
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08035
- Hospital Universitari Vall d'Hebron Research Institute
-
-
Madrid
-
Madrid, Madrid, Spania, 28006
- Hospital Universitario de La Princesa
-
-
Valencia
-
Valencia, Valencia, Spania, 46026
- Hospital Universitario Politécnico La Fe
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:
- La Princesa University Hospital
- Vall d'Hebron University Hospital
- Marqués de Valdecilla University Hospital
- Valladolid University Clinical Hospital
- Donostia University Hospital
- Lozano Blesa University Clinical Hospital
- La Fe Polytechnic University Hospital
Beskrivelse
Inclusion Criteria:
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
Exclusion Criteria:
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Patients with migraine under treatment with monoclonal antibodies against CGRP
Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included. |
The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication. Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia. Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Biomarkers of positive initial response to monoclonal antibodies
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response). |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sustained response factors
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Sustained response after discontinuation of the anti-CGRP antibody
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Non-maintained pharmacological response relation with biomarkers
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Time until relapse after discontinuation of the anti-CGRP antibody
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
Tidsramme: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PI 23- 3054
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .